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Abstract 
Background: The hyperreactive malarial splenomegaly (HMS) represents a chronic, potentially fatal complication of 
malaria. Case definition includes: gross splenomegaly, high level of anti-malarial antibody and IgM, response to long-
term anti-malarial prophylaxis. In this study, a large series of patients not fully meeting the case definition was tenta-
tively classified as early hyperreactive malarial splenomegaly (e-HMS). The main research questions was: does “e-HMS” 
tend to evolve to the full-blown syndrome? And if so, what are the main factors influencing this evolution?
Methods: Retrospective, longitudinal study. The patient database was searched to retrieve all potentially eligible 
patients. e-HMS was defined by splenomegaly of any size (with or without raised IgM), high anti-malarial antibody 
titre and exclusion of other causes of splenomegaly. The clinical outcome at following visits was analysed in relation to 
re-exposure to malaria, and to treatment (only part of the patients with e-HMS were treated with a single anti-malarial 
treatment and advised to follow an effective anti-malarial prophylaxis, if re-exposed). The association of the outcome 
with the main independent variables was first assessed with univariate analysis. A stepwise logistic regression model 
was then performed to study the association of the outcome with the main independent variables.
Results: One hundred and twenty-six subjects with e-HMS were retrieved. Eighty-one had at least one follow-up 
visit. Of 46 re-exposed to malaria for a variable period, 21 (46 %) had progressed, including 10/46 (22 %) evolving 
to full-blown HMS, while of 29 patients not re-exposed, 24 (93 %) had improved or cured and five (7 %) progressed 
(p < 0.001). At logistic regression re-exposure was confirmed as a major risk factor of progression (OR 9.458, CI 
1.767–50.616) while treatment at initial visit was protective (OR 0.187, CI 0.054–0.650).
Conclusion: e-HMS should be regarded as a clinical condition predisposing to HMS. Although the case definition 
may include false positives, e-HMS should be treated just as the full-blown syndrome. A single anti-malarial treatment 
is probably adequate, followed by effective prophylaxis for patients exposed again to malaria transmission.
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Background
The hyperreactive malarial splenomegaly (HMS), pre-
viously referred to as tropical splenomegaly or tropical 
splenomegaly syndrome (TSS) is a chronic complica-
tion of malaria. Patients have high levels of anti-malar-
ial antibody [1, 2], as a result of the chronic antigenic 
stimulation, which seems to be an important factor in 
the development of the syndrome. Although the exact 
mechanism is uncertain, evidence suggests that repeated 
or chronic exposure to malaria elicits exaggerated stimu-
lation of polyclonal B lymphocytes, leading to excessive 
and partially uncontrolled production of immunoglobu-
lin M (IgM) as the initiating event [3]. IgM is polyclonal 
and there is no evidence to attribute the syndrome to any 
malaria species in particular [1], although Plasmodium 
falciparum is by and large the predominant species in 
the countries where the syndrome has been described 
[4]. A history of chronic splenic enlargement [5, 6] differ-
entiates HMS from the splenomegaly observed in acute 
malaria.
At the very beginning patients might not have any 
symptoms. If HMS is not cured most patients report 
unspecific symptoms like asthenia, abdominal discom-
fort and other. Patients adapt physiologically to chronic 
anaemia, which develops due to hypersplenism [7, 8] and 
become symptomatic when it is severe. Hepatomegaly is 
also common. Main complications are represented by an 
increasing frequency of infectious diseases and haemo-
lytic disorders, and mortality may exceed 50  % if the 
syndrome is left untreated [9]. In particular, especially 
pregnant women are susceptible to episodes of massive 
haemolysis, which are usually preceded by febrile epi-
sodes [10].
After excluding other known causes of splenomegaly, 
“tropical splenomegaly syndrome” (the former name 
of HMS) was defined as a separate entity and Fakunle 
set clear diagnostic criteria in 1981 [11], that were sub-
sequently reviewed by Bates et al. [12]. The major diag-
nostic criteria include: massive splenomegaly, high 
anti-malarial antibody titre, high IgM value (local 
mean  +2SD) and a clinical-immunological response to 
prolonged anti-malarial treatment or to a prophylactic 
regimen [13]. HMS has also been diagnosed in expatri-
ates after a prolonged period of exposure in endemic 
areas [14].
At the centre for tropical diseases (CTD), in the last 
25 years, a relevant number of cases have been observed, 
both in immigrants from malaria endemic areas and in 
Italian citizens who had lived for a prolonged period in 
such areas. Furthermore, over the years it has been also 
observed that some patients, who initially had only some 
of the case definition criteria of the HMS (in particular 
with light or moderate, instead of massive splenomegaly), 
once examined again after a further stay of variable dura-
tion in endemic areas, developed all the HMS criteria. 
It was, therefore, supposed that it is possible to identify 
and diagnose an early stage of HMS, here below defined 
as “early HMS” (e-HMS). As the latter was not consid-
ered in medical literature, these patients were usually not 
treated, unless malaria parasites were identified in blood 
(thus defining a chronic malarial infection). Once the 
early syndrome was hypothesized, a number of patients 
considered potentially affected were then treated for 
malaria and advised to follow an effective prophylaxis in 
case they had to go back to endemic areas.
The main objectives of this research were:
(a) to assess if e-HMS, that has not been so far consid-
ered as a nosological entity, tends to evolve to the 
full-blown HMS;
(b) if so, if the evolution of e-HMS is significantly differ-
ent between patients re-exposed and not re-exposed 
to malaria transmission, and
(c) if the evolution of e-HMS is significantly different 
between patients who are treated for malaria versus 
those who are not.
Methods
Study design
Retrospective, longitudinal study aiming to identify 
patients with e-HMS observed from 1 January 1990 to 
31 January 2014 and subsequently visited at follow-up (at 
least once after initial visit). The population included in 
the analysis had to be selected according to the following 
case definition of e-HMS:
  • anti-malarial antibody titre (IFAT-Biomé-
rieux) > 1/160, PLUS:
  • splenomegaly (echographic longitudinal diam-
eter ≥  12  cm or palpable lower pole of the spleen) 
AND/OR
  • high IgM level (≥2.5 g/L), AND
  • no other identified causes of splenomegaly or of 
raised IgM, such as: schistosomiasis, HBV, HCV, 
HIV, brucellosis, leishmaniosis, autoimmune disease, 
cirrhosis, haemoglobinopathies, and other haema-
tological conditions, such as leukemia, lymphoma, 
Waldenstrom disease.
Patients with splenomegaly or with raised IgM, 
observed during the study period, and without any of the 
mentioned alternative diagnoses, were retrieved from 
the CTD patient database as indicated below. Those with 
anti-malarial antibody titer  ≥160, and/or with history 
of  ≥3  years stay in malaria-endemic areas and report-
ing ≥10 acute malaria episodes, were initially included. 
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Patients meeting the case definition of full-blown HMS 
as outlined above were excluded. The remaining subjects, 
meeting the tentative case definition of e-HMS, were 
retained for further analysis. The main epidemiological, 
clinical and laboratory findings were recorded at baseline. 
From baseline, patients were then traced prospectively 
for any further visit and, in case any follow-up contacts 
were recorded, follow up data was included in the study 
file. For all patients having at least a follow-up visit after 
initial observation, the last follow-up visit was considered 
for the outcome assessment in relation with re-exposure 
or not to malaria-endemic areas and to treatment or not 
at initial visit, as well as with the other main independent 
variables.
Data source
CTD patient database (electronic since 1995, paper-
based from 1990 to 1994). Echography of the upper abdo-
men, as well as immunoglobulin dosage and anti-malarial 
antibody testing, were part of the routine screening of 
patients with a history of a long stay (>1 year) in a malaria 
endemic country and reporting several malaria episodes.
Data entry and data elaboration
Data was exported to a pre-structured Excel file (Addi-
tional file 1), including:
  • (T1) baseline;
  • (T2) short-term follow up visits (1–6  months after 
first observation);
  • (T3) long-term follow up visits (≥6 months after first 
observation).
Definition of main diagnostic criteria for e‑HMS
  • Splenomegaly: massive if bipolar diameter ≥  16  cm 
or if lower pole beyond the umbilical line; moder-
ate, ≥14 and <16 cm or lower pole palpable without 
inspiration; mild, ≥12 and <14 cm or lower pole pal-
pable on inspiration only; normal spleen, <12 cm or 
lower pole not palpable.
  • Anti-malarial titre: Indirect Fluorescent Antibody 
Test (IFAT, Biomérieux) titre  ≥  1:160. In the few 
cases of missing serology, a prolonged stay in an 
endemic area (≥3  years) and over 10 malarial epi-
sodes reported, was considered equivalent to a high 
anti-malarial antibody titer.
  • Serum IgM level, two standard deviations above the 
local mean, corresponding to ≥2.5 g/L.
Definition of follow‑up criteria
  • Cured: absence of splenomegaly and normal IgM 
titer;
  • Improved:  ≥0.5  cm decrease of the spleen diam-
eter, or unchanged spleen diameter and  ≥0.5  g/dL 
decrease of IgM level;
  • Unchanged:  <0.5  cm or no variation of the spleen 
diameter and <0.5 cm or no variation of IgM level;
  • Progressed:  ≥0.5  cm increase of the spleen diam-
eter, or unchanged spleen diameter and  ≥0.5  g/dL 
increase of IgM level;
  • HMS: patients with e-HMS at initial visit, meeting 
the case definition of full-blown HMS (as resumed in 
Introduction) at follow-up.
Laboratory methods for malaria detection
Patients were screened for Plasmodium using one of the 
following methods: QBC Malaria Test (QBC Diagnostics 
Inc, Philipsburg, US) or Malaria antigen Rapid Detection 
Test (RDT) (different commercial devices were used over 
time). For all positive results, confirmation with micros-
copy was also carried out.
Statistical analysis
Data was analysed using the software STATA IC 14 
(StataCorp, 4905 Lakeway, College Station, TX, 77845, 
USA) [15]. For categorical variables the absolute, rela-
tive and cumulate frequencies were calculated. For 
continuous variables, the median and IQ range were 
considered. The univariate association between categori-
cal variables was evaluated using the χ2 test. The Fisher 
exact test was used if appropriated. A stepwise logistic 
regression model with forward selection was performed 
to study the association of the main dependent variable 
(outcome at follow-up) with the independent variables 
such as: sex; ethnicity; re-exposure to malaria; pres-
ence/absence of symptoms and of malaria parasites at 
first visit; treatment or not at first visit; age; time elapsed 
between the first observation and follow-up. Potential 
interaction among the variables was also studied with 
the same model. Significance values for entry in (pe)/
removal from (pr) the model were set at 0.10 and 0.15, 
respectively.
Ethical issues
Subjects were anonymously coded in the database, 
unlinked from any information identifying the source 
individuals. Although the study was retrospective and no 
action on patients was involved, the study protocol was 
nevertheless submitted to the Ethics Committee of the 
Coordinating Site (Comitato Etico Provinciale di Verona) 
for approval. The latter acknowledged the study protocol 
and formally authorized the study (protocol n. 43713 of 
29th September, 2014).
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Results
Study population
The patient flow is resumed in Fig. 1. From the initially 
retained sample of 171 patients, 45 were full-blown 
HMS. Among the 126 patients with e-HMS, 81 (64.3 %) 
had at least one follow up visit. Forty-six had been re-
exposed to malaria transmission in endemic countries 
before follow-up, 32 had remained in Italy, and for three 
patients this information was missing. Of the 81 subjects 
with follow-up, 56 (70 %) were treated at initial visit (28 
re-exposed, 25 not re-exposed and three with unknown 
re-exposure status), and 24 were not (17 re-exposed and 
7 not re-exposed), while for one (re-exposed) this infor-
mation was missing.
Most of the subjects included met the main case defi-
nition criteria as outlined in “Methods”. Anti-malarial 
antibodies were available for 86/97 Caucasian patients 
and for 20/29 non-Caucasians, while in the other 
cases the inclusion was based on the alternative crite-
ria of ≥3 years stay in malaria-endemic areas and ≥10 
acute malaria episodes. The median value of anti-malar-
ial antibody titre was 2560 for Caucasians (IQ range 
1280–5120) and 1280 for non-Caucasians (IQ range 
320–5120).
Baseline characteristics of the study population: patients 
with at least one follow‑up visit versus lost to follow‑up
Table  1 compares the main baseline characteristics 
between the e-HMS subjects who were followed-up and 
those who were lost. A substantial similarity is observed 
between the two subgroups.
Baseline characteristic of subjects re‑exposed vs not 
re‑exposed to malaria transmission
Most subjects (46/78 or 59 %) were re-exposed to malaria 
transmission before follow-up (this data was missing for 
three patients). Table 2 summarizes the baseline charac-
teristics of the two groups.
The median age of re-exposed subjects was higher: 
54 years versus 37.5 years (p = 0.003). Most patients re-
exposed were Caucasian (45 vs one, p  <  0.001). There 
was no significant gender difference. The average dura-
tion of exposure to malaria before observation was simi-
lar and so were most clinical and laboratory findings. 
The median diameter of the spleen was higher in not re-
exposed subjects (15 vs 14 cm, p = 0.011) and so was the 
median RBC count (4.6 vs 4.1 × 106/µL, p = 0.042), but 
the Hb value was similar in the two groups.
Baseline characteristics of e‑HMS group, treated vs 
untreated
The characteristics of the e-HMS subjects who received/
did not receive an anti-malarial treatment are summa-
rized in Table  3. The two groups were similar for the 
variables considered, but for the presence of malaria par-
asites in blood (26 vs 26 in the treated group, 7 vs 0 in 
the untreated group, p =  0.014) and for the median Plt 
count, (158 vs 201 × 103/µL, p = 0.014).
Symptoms
Most of the patients were symptomatic at first observa-
tion. Asthenia was the most frequently reported symp-
tom, present in 44/97 Caucasians (45  %) and in 7/29 
Fig. 1 Study flow-chart
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non-Caucasians (24 %). Fever (most often low-grade) was 
present in 37/97 Caucasians (38 %) and in 8/29 non-Cau-
casians (28 %).
Parasite detection
Overall, Plasmodium was searched in 87 subjects out of 
126 (59.2 %), with a positive result (usually at low para-
site density) in 36/87 (41.4  %). P. falciparum was the 
species involved in all cases, but for one case of Plas-
modium malariae and one of Plasmodium vivax, both 
in Caucasians. Among Caucasians, positive results were 
27/67 overall, of which 3 (11 %) had only a positive RDT 
or QBC (with negative blood film), and of the remaining 
24, 12 (50 %) had a parasite density <1000/µL (of which 3 
with  <50/µL). The highest value of parasite density was 
10,500/µL, roughly corresponding to 0.25  %. Among 
non-Caucasians, positive results were 9/20 overall (45 %), 
of which 2 (22 %) had only a positive RDT or QBC, and 
of the remaining 7, 5 (71 %) had a parasite density <1000/
µL (of which 2 with density <50/µL). The highest value of 
parasite density was 21,500/µL, roughly corresponding to 
0.5 %.
Outcome at follow‑up of patients with e‑HMS re‑exposed 
versus not re‑exposed to malaria transmission
The results of univariate analysis are reported in Table 4. 
If unexposed, the majority improved (20/32  =  62.5  %) 
or even healed (7/32  =  21.9  %), and none progressed, 
Table 1 Baseline characteristics of  subjects diagnosed with  early HMS (e-HMS), with  follow-up (Follow up) versus  lost 
to follow up (Lost)
Characteristic All (n = 126) Follow up (n = 81) Lost (n = 45) p value
Age, years [median (IQ range)] 53.7 (38.9–61.4) 53.4 (38.9–60.9) 55.9 (41.5–62.7) 0.485
Gender (F/M) 52/74 31/50 21/24 0.359
Ethnicity (Caucasian/other) 97/29 62/19 35/10 0.875
Exposure, years [median (IQ range)] 20.0 (11.5–29.5) 20.0 (12.5–28.5) 19.5 (10.0–31.0) 0.839
Presence of symptoms, Y/N 114/10 74/6 40/4 0.742
Spleen diameter, cm [median (IQ range)] 14.0 (13.0–15. 0) 14.0 (13.0–15. 0) 13.5 (12.9–15.0) 0.083
Presence of hepatomegaly, Y/N 43/81 30/50 13/31 0.373
Hb, mg/dL [median (IQ range)] 12.4 (11.0–13.9) 12.3 (11.0–13.3) 12.75 (11.0–15.2) 0.264
RBC × 106/µL [median (IQ range)] 4.2 (3.7–4.7) 4.1 (3.7–4.7) 4.5 (3.7–5.0) 0.233
Plt × 103/µL [median (IQ range)] 173.0 (135.0–228.0) 170.0 (137.0–217.0) 179.0 (127.0–259.0) 0.367
ESR, mm/h [median (IQ range)] 26.0 (12.0–50.0) 25.0 (14.0–47.0) 28.0 (9.0–56.0) 0.892
IgM, g/L [median (IQ range)] 2.8 (1.9–3.7) 2.9 (1.9–3.8) 2.8 (1.9–3.6) 0.727
Plasmodium in blood, Y/N 36/51 26/33 10/18 0.460
Table 2 Baseline characteristics of  subjects diagnosed with  early HMS (e-HMS), re exposed versus  not re exposed 
to malaria transmission before follow up
Info on exposure missing in three cases
Characteristic All (n = 81) Re‑exposed (n = 46) Not re‑exposed (n = 32) p value
Age, years [median (IQ range)] 53.4 (38.9–60.9) 54.0 (49.3–61.0) 37.5 (25.2–60.1) 0.003
Gender (F/M) 31/50 19/27 11/21 0.536
Ethnicity (Caucasian/other) 62/19 45/1 14/18 0.000
Exposure, years [median (IQ range)] 20.0 (12.5–28.5) 17.5 (9.5–29.0) 22.0 (16.5–27.5) 0.124
Presence of symptoms, Y/N 74/6 40/5 31/1 0.391
Spleen diameter, cm [median (IQ range)] 14.0 (13.0–15. 0) 14.0 (12.9–15.0) 15.0 (14.0–15.5) 0.011
Presence of hepatomegaly, Y/N 30/50 20/25 10/22 0.242
Hb, mg/dL [median (IQ range)] 12.3 (11.0–13.3) 12.3 (11.4–13.2) 12.3 (10.8–14.0) 0.870
RBC × 106/µL [median (IQ range)] 4.1 (3.7–4.7) 4.1 (3.7–4.3) 4.6 (3.8–4.8) 0.042
Plt × 103/µL [median (IQ range)] 170.0 (137.0–217.0) 169.0 (149.5–214.0) 183.0 (123.0–217.5) 0.674
ESR, mm/h [median (IQ range)] 25.0 (14.0–47.0) 25.0 (13.0–51.0) 23.5 (14.5–41.0) 0.905
IgM, g/L [median (IQ range)] 2.9 (1.9–3.8) 2.9 (2.1–4.7) 2.2 (1.6–3.6) 0.229
Plasmodium in blood, Y/N 26/33 14/16 11/15 0.743
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while almost half of subjects re-exposed progressed 
(11/46  =  23.9  %) or evolved to full-blown HMS 
(10/46 = 21.7 %) (p < 0.001).
Outcome of early‑HMS patients treated versus not treated 
for malaria at initial visit
The results are reported in Table  5. Most of the 56 
treated patients healed (15/56  =  26.8  %) or improved 
(29/56  =  51.8  %), while almost half of the untreated 
patients progressed (5/24 =  20.8  %), or evolved to the 
full-blown-HMS (6/24 = 25.0 %) (p = 0.040). The final 
model of stepwise logistic regression was based on 77 
observations and resulted globally statistically sig-
nificant (p  =  0.0004). The goodness of fit was modest 
(pseudo R2 = 0.2137) suggesting the need of confirming 
the results with a higher number of observations and/
or with the association of other possible predictors, if 
any. Variables significantly associated with outcome in 
the final model (Table  6) were treatment, presence of 
asthenia and re-exposure to malaria-endemic areas, 
while age was close to significance. Re-exposure (OR 
9.458, p  =  0.009) and presence of asthenia at initial 
observation (OR 4.188, p =  0.035) were independently 
associated with progressed outcome, while treatment 
resulted associated with improved outcome (OR 0.187, 
p = 0.008).
Discussion
Baseline characteristics of the study population
As 1/3rd of the study subjects were lost at follow-up, 
it was first assessed if this group was similar for the 
main baseline characteristics to the group of subjects 
Table 3 Baseline characteristics of subjects diagnosed with early HMS (e-HMS), with follow-up: treated versus untreated
a Info on treatment missing in one case
Characteristic All (n = 81)a Treated (n = 56) Not treated (n = 24) p value
Age, years [median (IQ range)] 53.4 (38.9–60.9) 54.0 (36.09–60.9) 49.8 (42.5–58.2) 0.502
Gender (F/M) 31/50 22/34 9/15 0.881
Ethnicity (Caucasian/other) 62/19 42/14 19/5 0.688
Exposure, years [median (IQ range)] 20.0 (12.5–28.5) 20.0 (13.0–28.5) 19.0 (13.0–31.5) 0.677
Presence of symptoms, Y/N 74/6 54/2 20/4 0.063
Spleen diameter, cm [median (IQ range)] 14.0 (13.0–15. 0) 14.0 (13.3–15. 0) 14.4 (13.0–15.0) 0.601
Presence of hepatomegaly, Y/N 30/50 20/36 10/14 0.614
Hb, mg/dL [median (IQ range)] 12.3 (11.0–13.3) 12.3 (10.7–13.3) 12.4 (11.9–13.9) 0.154
RBC × 106/µL [median (IQ range)] 4.1 (3.7–4.7) 4.1 (3.7–4.6) 4.4 (4.0–4.7) 0.227
Plt × 103/µL [median (IQ range)] 170.0 (137.0–217.0) 158.0 (129.0–208.0) 201.0 (165.5–250.0) 0.014
ESR, mm/h [median (IQ range)] 25.0 (14.0–47.0) 26.5 (14.5–42.0) 23.0 (16.5–41.5) 0.319
IgM, g/L [median (IQ range)] 2.9 (1.9–3.8) 2.9 (1.7–4.3) 2.8 (2.1–4.1) 0.693
Plasmodium in blood, Y/N 26/33 26/26 7/0 0.014
Table 4 Outcome at follow-up of patients with e-HMS, re-exposed versus not re-exposed to malaria transmission
p < 0.001, Fisher’s exact
Outcome Cured % Improved % Unchanged %  Progressed % HMS % Tot
Re-exposed 13 28.3 12 26.1 0 0 11 23.9 10 21.7 46
Not re-exposed 7 21.9 20 62.5 5 15.6 0 0 0 0 32
Tot 20 25.6 32 41.0 5 6.4 11 14.1 10 12.8 78
Table 5 Outcome at follow-up of patients with e-HMS, treated versus not treated at initial observation
p = 0.040, Fisher’s exact
Outcome Cured % Improved % Unchanged %  Progressed % HMS % Tot
Treated 15 26.8 29 51.8 3 5.4 5 8.9 4 7.1 56
Not treated 5 20.8 6 25.0 2 8.3 5 20.8 6 25.0 24
Tot 20 25.0 35 43.8 5 6.3 10 12.5 10 12.5 80
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with follow-up, which was indeed the case (Table  1). 
The same comparison was subsequently performed for 
the two main independent variables that were hypoth-
esized to be associated with the final outcome: re-expo-
sure or not to malaria and treatment at the initial visit. 
Here again, the two groups were substantially similar 
(Table 2), with a few important exceptions. The median 
age of the re-exposed group was significantly higher 
which was clearly correlated with ethnicity, as almost 
all re-exposed subjects were Caucasians, mostly mis-
sionary people who returned to the African country of 
residence, while more than half of the not re-exposed 
group was composed of immigrants who had come to 
Italy to stay. The difference in spleen diameter may find 
a logical explanation (it is possible that subjects with a 
bigger spleen were more frequently advised to avoid re-
exposure) or be simply due to chance, similarly to the 
difference in RBC count (but not in Hb value). Treated 
versus untreated subjects (Table  3) were also similar, 
but for the presence of detectable Plasmodium in blood 
and for the platelet count (the two variable are corre-
lated, as malaria is known to cause a transient drop in 
platelet count). Patients were more likely to be treated 
if malaria parasites were found in blood, which is by 
no mean unexpected. All potentially confounding vari-
ables were included in the log regression model.
Outcome analysis
This retrospective, longitudinal study aimed to describe 
the clinical evolution of subjects presenting a history of 
long term exposure to malaria transmission and a sple-
nomegaly (any spleen size), with or without a raised IgM 
level in blood. After excluding other possible causes 
of splenomegaly, a tentative definition of e-HMS was 
devised, as described in the “Methods”.
It has been reported that the development of HMS can 
be influenced by various aspects, including genetic pre-
disposition [16–18], but the evaluation of these aspects 
was not a purpose of this study.
Returning to an endemic area for malaria proved to be 
a risk factor for the evolution of the syndrome. Almost 
half of all the subjects re-exposed to malaria progressed, 
versus none of those who remained in Italy until follow-
up. Even more importantly, almost a quarter of the re-
exposed group evolved to a full-blown HMS. Therefore, 
although the case definition of e-HMS may not be specific 
and may include patients with other (albeit unrecognized) 
causes of splenomegaly, the risk of evolution to HMS, a 
severe disease with high mortality, justifies in itself the 
recognition of the early stage of the disease, that should be 
properly treated. Treatment appeared to be independently 
protective against evolution of e-HMS to full-blown HMS.
Study limitations
The main limitations of this study are inherent to the ret-
rospective study design, in particular:
  • loss at follow-up of several patients: the follow-up 
data was obtained retrospectively from the patients 
returned (often occasionally) to the observation after 
the first contact; anyway for about 2/3rd of the study 
subjects follow-up data was available, moreover as 
mentioned above the baseline characteristics of the 
two groups were in all similar;
  • not uniform follow-up time, for the same reasons 
outlined above; however, this variable was duly 
included in the log regression model;
  • differences between the two main groups of re-
exposed/not re-exposed and of treated/not treated 
for some characteristics as discussed above;
  • on logical grounds, for treatment at initial observa-
tion to be really effective, long term prophylaxis and/
or frequent/intermittent anti-malarial treatment 
are also necessary [19, 20]. Unfortunately, while the 
subjects who were treated were of course also rec-
ommended to follow an effective prophylaxis if re-
exposed, self-reported data on compliance with this 
recommendation proved not to be reliable and it was 
not possible to include this variable in the model.
However, at multivariate analysis including most 
potential predictors, the main findings (the tendency of 
e-HMS to evolve in subjects re-exposed to malaria, and 
in those not treated) was robust. Asthenia was the only 
Table 6 Summary results of stepwise logistic regression
Odds ratio (95 % conf. interval) of the risk of worsening outcome for the independent variables retained by the model and respective p values
Variable Odds ratio (95 % conf. interval) p value
Treatment at initial visit 0.1865272 (0.0535228–0.6500476) 0.008
Age 0.9510769 (0.9045759–0.9999683) 0.050
Presence of asthenia at initial visit 4.187701 (1.105679–15.8607) 0.035
Re-exposure to malaria-endemic areas before follow-up 9.457626 (1.767157–50.61614) 0.009
Constant 2.230569 (0.3019927–16.47536) 0.432
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symptom seemingly influencing the risk of evolution, 
although it cannot be excluded a chance association.
Conclusions
It’s possible to identify an early stage of HMS, which has 
been defined as e-HMS, that tends to evolve into a full-
blown HMS if malaria antigenic stimulus persists and if 
subjects are not treated for malaria. e-HMS is character-
ized by a spleen size ≥12 cm, even in the absence of high 
values of IgM level, or by raised IgM without splenomeg-
aly, in subjects with a history of long term exposure to 
malaria transmission, and with high titre of anti-malarial 
antibodies. The case definition of the syndrome should be 
updated in order to include criteria to diagnose e-HMS, 
that should be recognized and treated. Although the 
diagnostic criteria of e-HMS may not be highly specific 
and include false positive subjects (with other causes of 
splenomegaly), treatment is warranted even if diagnostic 
certitude is lacking, considering the risk of evolution to 
HMS and its complications.
A randomized controlled trial would be the best way to 
rigorously assess the efficacy of initial anti-malarial treat-
ment, followed by prophylaxis or possibly by intermittent 
anti-malarial treatment in case of re-exposure, on the 
evolution e-HMS. However, undertaking a similar trial 
may prove difficult in the field, also considering the nec-
essarily long follow-up time. On the other hand, a mul-
ticentre retrospective study on a larger series of patients 
observed in non-endemic countries could corroborate 
the findings of this research and lay a more robust basis 
for its conclusions.
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